Loading...

IOVA IOVANCE BIOTHERAPEUTICS INC Earnings Reports 8-K Filing

VNC

V

IOVANCE BIOTHERAPEUTICS INC

(IOVA)

2026 8-K

Board Departure

Financial Update

Revenue Guidance Update

Financial Results Update

Corporate Presentation Update

New Sales Agreement

Product Approval Announcement

Financial Statements

Management Change

Office Relocation

Corporate Presentation Update

Financial Results

Presentation Update

Earnings Reports

Submission of Marketing Aut...

Annual Meeting of Stockholders

Presentation Update

Clinical Data Announcement

Financial Results Announcement

Settlement of Stockholder D...

Retirement and Nomination

Corporate Presentation Update

Financial Results Announcement

Sale of Common Stock

Underwriting Agreement

Financial Results and FDA A...

Presentation Update

Presentation Update

Earnings Reports

FDA Update on Lifileucel Ta...

Unauthorized Posting of Pre...

Earnings Release

Open Market Sale Agreement

Annual Meeting of Stockholders

FDA Accepts Biologics Licen...

Acquisition of Worldwide Ri...

Earnings Report

Appointment of Director

FDA Submission Completed

Earnings Release

Acquisition of Worldwide Ri...

Corporate Presentation Update

External Links:

On February 24, 2026, Iovance Biotherapeutics, Inc. reported its financial results for Q4 and the full year ended December 31, 2025, and announced an updated corporate presentation for healthcare conferences.

AI Assistant

IOVANCE BIOTHERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.